Apelin
An endogenous peptide ligand for the APJ receptor with cardiovascular and metabolic research relevance.
Also appears in: Other
Public product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary research area: Hormone. Also surfaces under Other for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 69 trials · 2997 PubMed results
Apelin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Apelin has 30 name-matched clinical trials (highest phase: Phase 3) and 2997 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What apelin is
Apelin is an endogenous peptide ligand of the APJ receptor and has been studied in cardiovascular, fluid-balance, and metabolic contexts.
Why it matters
It helps strengthen the library’s scientific credibility by covering important physiology peptides that are real and relevant even when they are not gray-market hype names.
Regulatory context
Apelin is not FDA approved as a standard peptide therapy in the United States.
Practical reading note
Apelin is the kind of peptide that makes the library smarter, not just bigger.